Charles River Laboratories beats revenue and EPS estimates and updates FY26 outlook
FROM THE WIRE · SEEKINGALPHA.COM
Charles River Laboratories press release (CRL): Q3 Non-GAAP EPS of $3.09 beats by $0.12. Revenue of $982.7M (-1.7% Y/Y) beats by $22.34M. Organic revenue growth of 4.7%.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishBeating estimates and updating the FY26 outlook can move the preclinical research company's shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 non-GAAP EPS was $3.09, beating estimates by $0.12.
- 02Revenue was $982.7M, down 1.7% year over year.
- 03Organic revenue growth was 4.7%.